Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today it has completed its previously announced acquisition of Kolltan Pharmaceuticals, Inc.
In a research report published Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $7.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, Inc.
In a research report published Monday, Brean Capital analyst Jason Wittes reiterated a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a …
Brean Capital analyst Jason Wittes was out with a research report, assuming coverage on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), with a Buy rating and price target of …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the second quarter ended June 30, 2016.
With more than 30,000 attendees, the American Society of Clinical Oncology (ASCO) annual meeting is the largest cancer conference in the world. As …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2016 “While the recent setback of the …
